Montelukast
- Atc Codes:R03DC03
- CAS Codes:151767-02-1#158966-92-8
- PHARMGKB ID:151767-02-1#158966-92-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Montelukast, Singulair; Belgium: Montelukast, Singulair; Bulgaria: Eonic, Montelukast, Singulair; Cyprus: Singulair; Czech Republic: Eonic, Montelukast, Monteratio, Singulair; Denmark: Singulair; Estonia: Astmir, Eonic, Monkasta, Montelukast, Singulair; Finland: Astecon, Montelukast, Singulair; France: Singulair; Germany: Montelubronch, Singulair; Greece: Montelukast, Singulair; Hungary: Eonic, Montelan, Montelukast, Singulair; Ireland: Montelukast, Singulair; Italy: Lukair, Lukasm, Montegen, Singulair; Latvia: Eonic, Montelukast, Singulair; Lithuania: Astmir, Eonic, Monkasta, Montecarde, Montelukast, Singulair; Luxembourg: Singulair; Malta: Singulair; Netherlands: Montelukast, Singulair; Poland: Asmenol, Astmirex, Drimon, Eonic, Hardic, Lukast, Milukante, Monkasta, Montelak, Montelukast, Montespir, Montessan, Montest, Promonta, Singulair, Symlukast; Portugal: Airathon, Deprive, Lukair, Montelucaste, Singulair, Singulergy; Romania: Montelukast, Singulair; Slovakia: Astmasan, Eonic, Montelukast, Singulair; Slovenia: Monkasta, Montelukast, Singulair; Spain: Singulair; Sweden: Montelukast, Singulair; UK: Singulair.
North America
Canada: Singulair; USA: Singulair.
Latin America
Argentina: Montrate, Rolast, Singulair; Brazil: Singulair; Mexico: Singulair.
Asia
Japan: Kipres, Singulair.
Drug combinations
Chemistry
Montelukast Sodium: C~35~H~35~ClNNaO~3~S. Mw: 608.17. (1) Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt, [R-(E)]-; (2) Sodium 1-[[[(R)-m-[(E)-2-(7-chloro-2-quinolyl)vinyl]-α-[o-(1-hydroxy-1-methylethyl)phenethyl]benzyl]thio]methyl]cyclopropaneacetate. CAS-151767-02-1; CAS-158966-92-8 (montelukast)(1995).
Pharmacologic Category
Anti-inflammatory Agents; Leukotriene Modifiers; Leukotriene Receptor Antagonist. (ATC-Code: R03DC03).
Mechanism of action
Selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene receptor.
Therapeutic use
Prophylaxis and chronic treatment of asthma. Relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. Prevention of exercise-induced bronchospasm.
Pregnancy and lactiation implications
Montelukast not teratogenic in animal studies; however, there are no adequate, well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use caution).
Unlabeled use
Acute asthma.
Contraindications
Hypersensitivity to montelukast or any component of the formulation.
Warnings and precautions
In rare cases, patients may present with systemic eosinophilia, sometimes with clinical features of vasculitis consistent with Churg-Strauss syndrome (causal association between montelukast and these underlying conditions not established). Caution when systemic corticosteroid reduction is considered in patients receiving montelukast. Chewable tablet contains phenylalanine. Montelukast will not interrupt bronchoconstrictor response to aspirin or other NSAIDs. Not FDA approved for use in reversal of bronchospasm in acute asthma attacks, including status asthmaticus.